A Novel Drug Carrier Targeting Matriptase

• 作 者: Libin Jiang Yunbin Jiang Cai Yuan Huajian Lin Zhuo Chen Mingdong Huang
• 机 构: College of Chemistry,FuZhou University State Key
• 出 处: 中国微米纳米技术学会纳米科学技术分会第四届年会暨2016国际纳米生物与医学学术会议
• 发表日期: 2016年5期
• 关键词: Human Serum Albumin drug carrier target matrix enzyme

　　Human Serum Albumin(HSA)is the most abundant protein in human plasma.As a transport protein,HSA has as many as seven drug binding sites and not cause human immunogenicity,and has good biodegradability.Thus HSA has been recognized as the ideal drug carrier[1].Although HSA has been reported to be abundant in inflammatory or tumor tissues due to increased capillary permeability and defective or absent lymphatic drainage systems,HSA itself does not actively target tumor cell properties[2].We use protein engineering technology to generate a recombinant protein of HSA fused with an agent targeting at matriptase,a surface protein over-expressed on cancer cells.The fusion protein possesses not only the drug loading ability of HSA,but also the tumor cell targeting.